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Detailed knowledge of the composition and structure of the spliceo-
some and its assembly intermediates is a prerequisite for understand-
ing the complex process of pre-mRNA splicing. To this end, we have
developed a tobramycin affinity-selection method that is generally
applicable for the purification of native RNP complexes. By using this
method, we have isolated human prespliceosomes that are ideally
suited for both biochemical and structural studies. MS identified >70
prespliceosome-associated proteins, including nearly all known U1
and U2 snRNP proteins, and expected non-snRNP splicing factors. In
addition, the DEAD-box protein p68, RNA helicase A, and a number of
proteins that appear to perform multiple functions in the cell, such as
YB-1 and TLS, were detected. Several previously uncharacterized
proteins of unknown function were also identified, suggesting that
they play a role in splicing and potentially act during prespliceosome
assembly. These data provide insight into the complexity of the
splicing machinery at an early stage of its assembly.
Spliceosomes, the complex enzymes responsible for pre-mRNAsplicing, consist of the U1, U2, U5, and U4U6 small nuclear
ribonucleoproteins (snRNP), plus numerous non-snRNP proteins.
During the stepwise assembly of spliceosomes, several distinct
complexes, which form in a defined order (i.e., E complex, followed
by A, B, and C), can be distinguished biochemically in vitro
(reviewed in refs. 1 and 2). Before association of snRNPs and
splicing factors, the pre-mRNA is bound by heterogenous nuclear
ribonucleoprotein (hnRNP) proteins, forming the H complex.
Spliceosome assembly is initiated by the ATP-independent inter-
action of the U1 snRNP with the 5 splice site which, in part,
involves base pairing between the U1 snRNA and the pre-mRNA.
This initial complex, termed E (early), also contains the U2 snRNP,
which at this stage is loosely associated with the pre-mRNA (3). In
a subsequent ATP-dependent step, the U2 snRNA base-pairs with
the branch site, leading to the stable association of the U2 snRNP
and formation of the A complex (also called the prespliceosome).
Contacts between snRNAproteins and the pre-mRNA that are
established during these early stages of spliceosome assembly play
crucial roles in the recognition and selection of splice sites. Thus,
regulation of alternatively spliced pre-mRNAs is often achieved by
modulating the association of spliceosomal components during E
and A complex formation. In a subsequent step, the U4U6.U5
tri-snRNP binds, leading to the formation of spliceosomal B
complex. After a major conformational change and the first trans-
esterification reaction of splicing, complex C is generated. After the
second transesterification step, the mRNA and excised intron are
released, and the spliceosome dissociates.
To date, 200 spliceosomal proteins have been identified in
mammals by MS (4–6). However, in these studies, a mixture of
purified splicing complexes was analyzed, preventing the assign-
ment of a particular protein to a specific splicing complex (4). More
recently, affinity selection with amylose beads of splicing complexes
formed on pre-mRNA prebound with the maltose-binding protein
has been used to isolate highly purified, native E and C complexes
(3, 7). However, to date, the protein composition of only the
spliceosomal C complex has been determined in detail by MS (7).
Thus, comprehensive information about the composition of splicing
complexes formed before the catalytic steps of splicing is currently
lacking. Similarly, approaches to isolate native splicing complexes
that are suitable for both biochemical and structural studies are
quite limited.
Here, we have developed a tobramycin affinity-selection method
and used it to purify preparative amounts of human prespliceo-
somes under native conditions. MS analyses revealed that prespli-
ceosomes are highly complex, with 70 associated proteins. These
studies provide detailed information about the composition of
prespliceosomes and suggest a role for the newly identified pre-
spliceosomal proteins during the early stages of spliceosome
assembly.
Methods
Plasmids, Oligonucleotides, and RNA Preparation. Oligonucleotides




TATACTAAGCCG). The J6f1 RNA aptamer (8) noncoding and
coding sequences, respectively, are underlined. The EcoRI-BamH1
insert of pMINX (9) was first cloned into the pGEM-3Zf(),
yielding pGEM-MINX. The HPV23 and HPV24 oligonucleotides
were annealed and cloned into BamH1SphI linearized pGEM-
MINX to yield pGEM MINX-T5. PCR with the HPV24 and M13f
primers generated the transcription template for the aptamer-
containing pre-mRNA. To obtain control pre-mRNA lacking the
aptamer, the PCR product was cleaved with BamHI. m7G-capped
transcripts were synthesized with T7 RNA polymerase (Mega-
Script, Ambion, Austin, TX). For quantitation, [-32P]UTP (3000
Cimmol; 1 Ci  37 GBq) was added to 0.23 M.
Solid-Phase Splicing Reaction and Spliceosome Purification. N-
hydroxysuccinimide-activated Sepharose 4 Fast Flow was derivat-
ized with 5 mM tobramycin as described (10). All further proce-
dures were performed at 4°C, unless otherwise stated. For affinity
selection, 4 binding buffer (4 BP)80 mM TrisHCl, pH 9.1 at
4°C4 mM CaCl24 mM MgCl22 mM DTT was freshly prepared.
The tobramycin matrix was blocked with 400 l of blocking buffer
(1 BP300 mM KCl0.1 mg/ml tRNA0.5 mg/ml BSA0.01%
Nonidet P-40) per 15-l aliquot by head over tail (HOT) rotation
overnight. The matrix was collected, and 400 l of a mixture
containing 60 pmol of tobramycin-tagged pre-mRNA and 40 g
of tRNA in binding buffer (1 BP145 mM KCl), were added to
15l of matrix and incubated for 1.5 h. The matrix was then washed
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three times (750 l each) with binding buffer containing 0.1%
Nonidet P-40. A pre-mRNA concentration of 22–25 nM was found
to be optimal for A complex formation (not shown). For a standard
splicing assay, four 15-l aliquots of matrix bound with pre-mRNA
were prepared. Splicing mix (1.5 ml) was added per 15-l matrix and
incubated at the indicated time and temperature with constant
HOT agitation. The splicing mix contained 35% HeLa cell nuclear
extract (11) in buffer D [20 mM Hepes-KOH, pH 7.9100 mM
KCl1.5 mM MgCl20.2 mM EDTA, pH 8.00.5 mM DTT0.5
mM PMSF10% (volvol) glycerol] and was supplemented with
25 mM KCl3 mM MgCl22 mM ATP20 mM creatine phosphate.
After splicing, reactions were chilled on ice, and the matrix was
collected by centrifugation. Matrix aliquots were pooled and
washed three times with 750 l of washing buffer (1 BP75 mM
KCl0.1% Nonidet P-40). Complexes were eluted by incubating
with 250 l of elution buffer (1 BP5 mM tobramycin145 mM
KCl2 mM MgCl2) with HOT rotation for 10 min. Typically,75%
of the bound complexes could be eluted. RNA and protein were
recovered and analyzed on 8.3 M urea10% polyacrylamide gels
(RNA) or by SDS10–13% PAGE (proteins), or for splicing, on 8.3
M urea-15% polyacrylamide gels.
Glycerol Gradient Centrifugation. Tobramycin eluate (220 l) was
loaded onto a 3.8-ml linear 10–30% glycerol gradient in 20 mM
Hepes-KOH, pH 7.975 mM KCl1.5 mM MgCl20.5 mM DTT.
Gradients were centrifuged for 107 min at 60,000 rpm in a Sorvall
TH660 rotor and harvested manually in 175-l fractions from the
top. RNA and protein were extracted from 100 l of every odd
fraction and analyzed as above.
Psoralen Crosslinking and Northern Blotting. Crosslinking was initi-
ated by adding psoralen (4-aminomethyl-4,5,8-trimethylpsoralen
hydrochloride) in DMSO (2 mgml) to 75 l of the even gradient
fractions to a final concentration of 40 gml and incubating for 10
min on ice. Samples were irradiated with 365 nm light for 30 min
at 4°C. RNA was recovered (12) and resolved on a 5% polyacryl-
amide8.3 M urea gel and analyzed by Northern blotting essentially
as described (13). DNA probes were generated by random priming
(Prime-it II, Promega) using pMINX DNA (pre-mRNA) or PCR-
amplified U1 or U2 snRNA coding sequences and [-32P]dATP
(6,000 Cimmol).
MS. Proteins separated by SDSPAGE were analyzed by matrix-
assisted laser desorptionionization MS (MALDI-MS) or liquid
chromatography-coupled tandem MS [LC-MSMS as described in
ref. 14; for details, see Supporting Methods, which is published as
supporting information on the PNAS web site, www.pnas.org) and
identified in the National Center for Biotechnology Information
nonredundant database by using MASCOT (Matrix Science, London)
as a search engine.
Results
Tobramycin Affinity Selection of Native Spliceosomal Complexes. To
affinity-purify spliceosomes under native conditions, we introduced
a 40 nt RNA aptamer at the 3 end of the adenovirus-derived
MINX pre-mRNA. This aptamer binds with high affinity (5 nM)
the aminoglycoside antibiotic tobramycin under physiological con-
ditions (8). Indeed, the aptamer-tagged MINX pre-mRNA bound
efficiently to tobramycin-derivatized Sepharose beads when the
binding reaction was performed at pH 9.1 in buffer containing 145
mM KCl and 1 mM Mg2. Under these conditions, 60–70% of
aptamer-tagged pre-mRNA, but only 2% of untagged pre-
mRNA, bound. More importantly, 80% of the bound pre-mRNA
could be eluted by incubating with 5 mM tobramycin. The aptamer-
tagged MINX pre-mRNA formed spliceosomal complexes and was
spliced in vitro with efficiencies and kinetics similar to that of
untagged MINX pre-mRNA (not shown). However, in the pres-
ence of nuclear extract, 1% of the tagged pre-mRNA bound to
the tobramycin matrix, suggesting that the RNA aptamer is no
longer accessible or the conditions used for splicing are suboptimal
for binding. Solid-phase splicing was thus performed by first
immobilizing the tagged pre-mRNA on the tobramycin matrix and
subsequently incubating with nuclear extract under splicing condi-
tions (Fig. 1A). The matrix was then washed extensively, and bound
material was eluted with tobramycin. RNA was isolated from the
eluate or reaction supernatant and analyzed by denaturing PAGE
(Fig. 1B). Splicing intermediatesproducts were first observed in
those complexes eluted from the matrix after 90 min and increased
markedly after 180 and 270 min, when mRNA product became
readily detectable (Fig. 1B, lanes 2–4). Thus, splicing proceeds with
Fig. 1. (A) Purification strategy. (B) Matrix-bound, aptamer-tagged pre-mRNA
is efficiently spliced. Solid-phase splicing was performed for the indicated times
at 30°C. RNA was recovered after elution (lanes 2–4) or from the reaction
supernatant (lanes 5–7; note that three times more supernatant than eluate was
assayed),analyzedbydenaturingPAGE,andvisualizedbyautoradiography.Lane
1, input pre-mRNA. The positions of the pre-mRNA and splicing intermediates
products are indicated on the right.
16720  www.pnas.orgcgidoi10.1073pnas.262483899 Hartmuth et al.
significantly reduced kinetics as compared with the nonimmobi-
lized, tagged MINX pre-mRNA, which yielded splicing products
already after 15 min (not shown). Most of the pre-mRNA remained
bound to the matrix even after extended incubation times, as
evidenced by the presence of only a very low level (maximally 7%)
of pre-mRNA and splicing intermediates in the supernatant of the
solid-phase splicing reaction (Fig. 1B, lanes 5–7). However, consis-
tent with it’s release from spliceosomes after the second step of
splicing, elevated amounts of excised intron were detected. These
results demonstrate that despite reduced reaction kinetics, the
matrix-bound, aptamer-tagged pre-mRNA is spliced efficiently
and, therefore, functional spliceosomal E, A, B, and C complexes
must be assembled as well.
Purification of Spliceosomal Complex A. To isolate prespliceosomes,
we performed solid-phase splicing for only 45 min to minimize
formation of BC complexes. The RNA and protein content of the
tobramycin eluate was then analyzed by denaturing PAGE or
SDSPAGE, respectively. As a control for nonspecific interactions,
an affinity selection was also performed in an identical manner, but
without pre-mRNA. As shown in Fig. 2A, in the absence of
pre-mRNA, relatively little snRNA was detected in the eluate (lane
2). By contrast, the eluate of the aptamer-tagged pre-mRNA (lane
1) contained similar amounts of pre-mRNA, U1 and U2 snRNA,
and only a low level of U4, U5, and U6 snRNA. This result indicated
that predominantly splicing complex A (andor potentially E) had
formed after 45 min and was subsequently eluted with tobramycin.
Correspondingly, the eluate from the affinity selection performed
with pre-mRNA exhibited a complex but distinct protein pattern,
whereas only a few proteins migrating in the 55- to 65-kDa range
were observed without pre-mRNA (Fig. 2A, compare lanes 3
and 4).
To characterize the affinity-purified splicing complexes in more
detail, the eluate was subjected to glycerol gradient centrifugation
(Fig. 2B), and the sedimentation behavior of complexes containing
32P-labeled pre-mRNA was compared with that of naked pre-
mRNA or affinity-selected H complexes (i.e., complexes formed
after a 15-min incubation with nuclear extract at 4°C). The vast
majority of complexes in the 45-min eluate peaked in fraction 11,
with a sedimentation value of 22S; minor peaks sedimenting at
28–42S were also observed. In contrast, naked pre-mRNA and H
complexes sedimented at 12 and 13S, respectively. Thus, the
45-min eluate seems to consist of a relatively homogeneous pop-
ulation of splicing complexes which exhibit an S value significantly
higher than the H complex, which is consistent with the idea that
predominantly complex A or E had been isolated. Indeed, analysis
of the RNA composition of the gradient fractions from the 45-min
eluate revealed equimolar amounts of the pre-mRNA and U1 and
U2 snRNAs in fractions 9–13 (Fig. 2C). These fractions were nearly
free of U4, U5, and U6 snRNAs, which, for the most part, were
found in either slower or faster migrating complexes; the latter,
which contain equimolar amounts of the pre-mRNA and all of the
major spliceosomal snRNAs (lanes 17–23), likely correspond to
spliceosomal complex B. Thus, glycerol gradient centrifugation
allows the efficient separation of H and B complexes from the
affinity-selected AE complexes.
Identification of E and A Complexes via RNA–RNA Crosslinking. E and
A complexes both contain U1 and U2 snRNPs, but a U2
pre-mRNA base pairing interaction is first observed in the A
complex (3). Thus, RNA–RNA crosslinking (12) was performed to
identify precisely complexes migrating in the 22S region of the
gradient. Gradient fractions were UV-irradiated in the presence of
psoralen, and the RNA was analyzed by Northern blotting, sequen-
tially probing for the pre-mRNA, U1 and U2 snRNAs (Fig. 3 A–C).
Multiple U1 snRNA-containing crosslinks, which peaked in frac-
tion 10, were observed in fractions 8–14 (Fig. 3C). Each of these
bands was also detected with a probe specific for the pre-mRNA,
confirming that they represent crosslinks between the splicing
substrate and U1 (Fig. 3A). In contrast, a U2pre-mRNA crosslink
was first detected in fraction 12, and its intensity gradually dimin-
ished from fraction 14 to 22 (Fig. 3B). In an independent experi-
ment, U2pre-mRNA crosslinks were also observed in fraction 11,
but not in the preceding fractions (not shown). Thus, fractions
11–14 contain predominantly the spliceosomal A complex, whereas
fractions 8–10 likely contain mainly E complex. A major U2U6
crosslink (verified by probing for U6; not shown), which is indicative
of complex B, peaked in fractions 16–22. However, only small
amounts were detected below fraction 14, confirming that fractions
11–13 (the A complex peak) are essentially free of complex B.
Protein Composition of Prespliceosomes. The protein composition of
the various gradient fractions was analyzed by SDSPAGE (Fig.
4A). A differential distribution of proteins across the gradient was
Fig. 2. (A) RNA and protein content of splicing complexes eluted with tobra-
mycin. Solid-phase splicing was performed for 45 min at 30°C in the presence
(lanes 1 and 3) or absence (lanes 2 and 4) of pre-mRNA, and the complexes were
subsequently eluted with tobramycin. RNA and protein were recovered, ana-
lyzed by PAGE, and visualized by silver staining. (B) Glycerol gradient analysis of
affinity-purified spliceosomal complexes. Naked pre-mRNA (F) or complexes
formedafter splicingfor15minat4°C(E)or for45minat30°C(Œ)were subjected
to 10–30% glycerol gradient centrifugation, and the percent of 32P-labeled
pre-mRNA in each fraction was determined by Cherenkov counting. (C) RNA
profile of the glycerol gradient fractionated, 45-min splicing complexes. RNA was
recovered from odd-numbered fractions and analyzed as in A. PRE, pre-mRNA; *,
contaminating RNAs.








observed, with high molecular weight U2 and U5 proteins peaking
in fractions 9–13 and 17–23, respectively. In addition, a distinct
protein pattern was found in the uppermost fractions, which
essentially lack pre-mRNA, suggesting that some proteins (or
snRNPs; see also Fig. 2C for RNA composition) have dissociated
during elution andor gradient centrifugation. Proteins present in
fractions 11–13 (the A complex peak) were pooled, fractionated by
SDSPAGE, and analyzed by MALDI-MS or, additionally, by
LC-MSMS.
More than 70 proteins were identified, including almost all
proteins known to be present in 12S U1 and 17S U2 snRNPs (Fig.
4B and Table 1). In contrast, no U4U6 and only high molecular
weight U5 andor tri-snRNP proteins were detected, confirming
the absence of large amounts of 25S U4U6.U5 tri-snRNPs.
Consistent with their known roles during EA complex formation,
most members of the SR protein family and the essential factors
U2AF65 and U2AF35 were identified. A large number of hnRNP
proteins and both m7G-cap-binding proteins (CBP20 and CBP80)
were also identified. In addition to the 17S U2 snRNP-associated
proteins hPrp5 and hPrp43, two more members of the DExHD-
box family of RNA unwindasesRNPases, namely, RNA helicase A
(DDX9) and p68, were detected. Several proteins implicated in
pre-mRNA splicing that appear to perform multiple roles in the
cell, such as Y-box-binding protein 1 (YB-1), TLSFUS, and
NFAR-2 (15–19), were identified, as well as the mRNA export
factors Aly and HuR (20–22). Interestingly, affinity-purified pre-
spliceosomes also contained a number of proteins not previously
known to be involved in splicing (Table 1).
Discussion
By using a tobramycin affinity-selection procedure, followed by
glycerol gradient centrifugation, it was possible to purify human
prespliceosomes (i.e., A complex) under native conditions. Several
lines of evidence support the conclusion that the complexes char-
acterized by MS represent prespliceosomes as opposed to BC
complexes: (i) both the tobramycin eluate and MS-analyzed gra-
dient fractions contained nearly equimolar amounts of pre-mRNA,
U1 and U2 snRNA, and only minimal amounts of U5 or U4U6
snRNA; (ii) most proteins identified by MS were U1 and U2 snRNP
proteins or known prespliceosomal-splicing factors; and (iii) RNA–
RNA crosslinks characteristic for BC complex were not observed.
Although several high molecular weight tri-snRNP proteins were
present in low amounts (as judged by silver staining of the protein
gel), no splicing factors known to associate first during or after B
complex formation were detected by MS (Table 1). Tri-snRNP
proteins could be present because of a low level of contaminating
BC complex (or a dissociation product thereof) or they may be
bona fide prespliceosomal components. Indeed, recent studies
Fig. 4. Protein content of the glycerol gradient fractionated, 45-min splicing
complexes (A), or of pooled gradient fractions 11–13 (B). Protein was recovered
from odd-numbered or pooled fractions and analyzed as in Fig. 2.
Fig. 3. Characterization of RNA–RNA interactions in gradient-fractionated spliceosomal complexes by psoralen crosslinking. Affinity-selected complexes were
fractionated on a 10–30% glycerol gradient, and crosslinking was performed with even-numbered gradient fractions (as indicated above each lane) or 2% of
unfractionated eluate (E lanes). In the left-most E lane, the eluate was UV-irradiated in the absence of psoralen to control for nonspecific crosslinking. RNA was
transferred to a nylon membrane that was hybridized sequentially with 32P-labeled probes specific for pre-mRNA (A) U2 snRNA (B) and U1 snRNA (C). The identity of
the crosslinked species is indicated on the right. AMT, psoralen; PRE, pre-mRNA; intPRE, internally crosslinked pre-mRNA.
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Table 1. Prespliceosome-associated proteins
Protein BN SC AC Feature
U1 snRNP
U1-70K 15  P08621 RRM, SR
U1A 28  P09012 2 RRM
U1C 34  NP003084 C2H2-ZF
17S U2 snRNP
SF3b155 3  AF054284 HEAT
SF3b145 4  NP006833 SAP
SF3b130 5  NP036558 CPSF A
SF3b49 20  NP005841 2 RRM
p14 37  AAK94041 RRM
SF3b14b 37  Q9UH06
SF3b10 n.s.  NP112577
SF3a120 6  NP005868 2 SURP, UBQ
SF3a66 16  NP009096 C2H2-ZF
SF3a60 17  NP006793 C2H2-ZF, SAP
U2A 30  P09661 LRR
U2B 31  P08579 2 RRM
17S U2-associated proteins
hPrp5 4  XP044949 SR, DEAD
SR140 4  BAA20790 RRM, SURP, SR
CHERP 5  NP006378 SURP, SR, G-patch
hPrp43 9  O43143 DEAH
SPF45 19  NP006441 G-patch, RRM
SPF31 26  NP055095 DnaJ
SPF30 27  AAC64086 Tudor
U5 snRNP
hPrp8 1  AAC61776
200K (Brr2) 2  O75643 DEIH, DxxH
116K (Snu114) 6  NP004238 GTP-EF2
102K (Prp6) 7  AAF66128 TPR
100K (Prp28) 7,8  NP004809 DEAD
tri-snRNP
110K (Snu66) 8  AAK49523 SR
Sm proteins
SmBB 3132  NP003082 Sm
SmD3 35  NP004166 Sm
SmD2 36  NP004588 Sm
SmD1 37  NP008869 Sm
SmE n.s.  NP003085 Sm
SmF n.s.  NP003086 Sm
SmG n.s.  NP003087 Sm
hnRNP proteins
U 6  NP114032 SAP, SPRY
R 17  NP005817 3 RRM, RGG
K 15  NP112552 3 KH, (RGG)
G 21  NP002130 RRM
A3 21  P51991 2 RRM
C1C2 22  NP004491 RRM
A2B1 23  NP112533 2 RRM
A1 2125  NP002127 2 RRM
SR proteins
SRp55 18  NP006266 2 RRM, SR
SRp40 23  Q13243 2 RRM, SR
9G8 2526  NP006267 RRM, SR
ASFSF2 27  Q07955 2 RRM, SR
SC35 26  A42701 RRM, SR
SRp30 27  NP003760 2 RRM, SR
SRp20 33  P23152 RRM, SR
Splicingtransport factors
CBP80 10  A54748 MIF4G
CBP20 35  P52298 RRM
U2AF65 15  NP009210 SR, 3 RRM
U2AF35 37*  NP006749 C3H1-ZF, RRM, SR
DDX9 3  Q08211 2 DSRM, DEAH
p68 14  NP004387 DEAH
NFAR-2 8  AAK07425 2 DSRM
TLSFUS 13  P35637 RRM, RANBP-ZF
YB-1 20  P16991 CSB
F238581 11  T02299 2 SURP, G-patch
hPrp19 18  NP055317 7 WD40
ALY 27  NP005773 RRM
HuR 25  NP001410 3 RRM
No previous connection to splicing
FLJ10839 3  XP167600 (CSB), SAP
RBM 5 6  NP005769 2 RRM, RanBP-ZF, C2H2-ZF, G-patch
ASR2B 7  AAK21006 RRM
E1B-AP5 8  NP008971 SAP, SPRY, (RGG)
CC1.3 12  NP004893 3 RRM, RS
FLJ21007 12  NP110421 UBA, Tudor
CD2BP2 19  NP006101 GYF
DnaJ hom. 6  NP055602 DnaJ
SMC1 4  BAA11495 P-loop, DA-box
SMC2 5  XP050024 P-loop, DA-box
*One peptide of U2AF35 was found in a band containing D1–D3, p14, and SF3b14b (Band 37). n.s., not shown in Fig. 4B. Human proteins are listed, with the names
ofselectedyeasthomologsshowninbrackets.BN,bandnumberinginFig.4B. SC(score):ahigh(),middle(),or low() scorewasassignedbasedonthepercent
sequence coverage determined by MALDI-MS andor the number of peptides identified by LC-MSMS. Note that the intensity of the gel bands was not taken into
account. AC, accession number as found in the protein sequence database of the ENTREZ databases at the National Center for Biotechnology Information. Feature,
listed features are derived from Prosite Scan (http:hits.isb-sib.chcgi-binPFSCAN) and Pfam (www.sanger.ac.ukSoftwarePfamindex.shtml).








suggest that the U4U6.U5 tri-snRNP complex interacts with the
pre-mRNA already at the early stages of splicing complex forma-
tion (23).
E and A complexes both contain U1 and U2 snRNPs, and, thus,
it is difficult to distinguish between them based on snRNA and
snRNP protein composition alone. However, two observations
support the conclusion that the complexes analyzed by MS are
predominantly A complexes: (i) the E complex protein SF1mBBP
was not detected, and (ii) psoralen crosslinking identified U1
pre-mRNA and U2pre-mRNA base-pairing interactions in the
MS-analyzed fractions. As the U2 snRNP first base-pairs with the
pre-mRNA in the A complex (3), these data provide the best
evidence that A complexes, as opposed to E complexes, were
analyzed. However, because of the intrinsically low efficiency of
psoralen crosslinking, we cannot rule out that gradient fractions
11–13 contain E complexes in addition to A. Gradient-fractionated,
affinity-purified splicing complexes did not withstand native
PAGE, and thus, this method could not be used to address this
question.
Most proteins identified in our affinity-purified prespliceosomes
are known to be involved in pre-mRNA splicing, a fact which attests
to the high purity of these complexes. Furthermore, nearly all
proteins expected to be present in mammalian prespliceosomes
were found, suggesting that the inventory of prespliceosomal pro-
teins presented in Table 1 is relatively complete. Interestingly, most
of the newly identified 17S U2 snRNP proteins, such as hPrp5,
hPrp43, SPF45, SF3b14, and SF3b10, were present in purified
prespliceosomes, consistent with the idea that they potentially
facilitate the association of U2 with the pre-mRNA (24). Based on
the combined total mass of the identified proteins, it is unlikely that
all of them are found in every prespliceosome. Indeed, some
proteins are clearly present in substoichiometric amounts, indicat-
ing that they are present in a subpopulation of the affinity-purified
complexes. As multiple members of the SR and hnRNP protein
families were detected, it is also likely that the complexes we have
analyzed may consist of a mixture of prespliceosomes containing
different subsets of these proteins.
In addition to SR, hnRNP, and snRNP proteins, 20 additional
polypeptides were identified. Each of the newly identified prespli-
ceosomal proteins, by virtue of their copurification with these
complexes, potentially plays a role in splicing. Several multifunc-
tional proteins, including YB-1 and TLSFUS were among those
identified, consistent with the idea that they are general splicing
factors and may act at an early stage of the splicing process. Indeed,
numerous studies have implicated TLSFUS in pre-mRNA splicing
(17, 25–27), and YB-1 is known to play a role in alternative splicing
(15). In addition to hPrp5 and hPrp43, the DExH-box proteins, p68
and RNA helicase A (DDX9) were also identified, suggesting that
they may contribute to the dynamics of spliceosome formation.
Correspondingly, recent evidence suggests that p68 destabilizes the
U15 splice-site interaction during spliceosome assembly (28).
MS revealed several proteins cofractionating with splicing com-
plex A whose precise function is not known. Three of them (CC1.3,
F238581, and RBM 5) contain domains (i.e., SURP, SR) that are
highly characteristic of pre-mRNA splicing factors, making them
good candidates for previously uncharacterized, bona fide prespli-
ceosomal proteins. Additional experiments are needed, however, to
clarify whether any are indeed involved in pre-mRNA splicing.
Although the majority of proteins identified by MS are most likely
bona fide splicing factors, some (e.g., hnRNP proteins) may bind
flanking regions of the pre-mRNA or internal intron sequences that
are not involved in the splicing process. Future studies with trun-
cated MINX pre-mRNAs should reveal if these and potentially
other proteins bind the substrate, but are not directly involved in
splicing. At present, it is also not clear which of the newly identified
prespliceosomal proteins are core components (i.e., are generally
present in prespliceosomes) and which may specifically associate
with the MINX pre-mRNA used in our studies.
Our data provide the first detailed inventory of the components
of the spliceosome at the early stages of its assembly. The charac-
terization of complexes formed at later stages should allow a clear
cut determination of the order and dynamics of the association of
proteins with the spliceosome during its assembly, catalytic activity,
and subsequent disassembly. Similarly, the affinity purification
method described here could potentially be used to identify sub-
strate-specific splicing factors, such as those involved in alternative
splicing events. Finally, the ability to isolate prespliceosomes, as well
as potentially other spliceosomal complexes under native condi-
tions, is a pivotal step toward the elucidation of their molecular
architecture. Ultrastructural investigations, e.g., electron micros-
copy, performed with native spliceosomal complexes at defined
stages of the splicing reaction, may ultimately reveal the structural
dynamics of the pre-mRNA-splicing machinery.
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